Innovent Reports Results of Sintilimab in P-III ORIENT-31 Study for EGFR-Mutated Non squamous Non-Small Cell Lung Cancer
Shots:
- The P-III ORIENT-31 study evaluates sintilimab with/out Byvasda + CT vs CT in a ratio (1:1:1) in patients with EGFR-mutated LA or metastatic nonsq. NSCLC who have progressed following EGFR TKI treatment
- The study has met its prespecified 1EPs of PFS at 1st interim analysis. In the ITT population- sintilimab + Byvasda & CT showed an improvement in PFS & Sintilimab + CT also showed PFS benefit over CT alone- the safety profile was consistent with that observed in previously reported studies of sintilimab & Byvasda & no additional safety signals were observed
- Additionally- the regulatory submission is currently under review in China for sintilimab as 1L treatment of ESCC
| Ref: PR Newswire | Image:Innovent
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com